Enoxaparin in acute coronary syndromes

Expert Review of Cardiovascular Therapy

Volumn 5, Issue 3, 2007, Pages 387-399

  Lee, Sinjin ^a   Gibson, C Michael ^b  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Acute coronary syndromes; Antithrombotic agents; Enoxaparin; Low molecular weight heparin; Percutaneous coronary intervention; Safety profile; STEMI; UA NSTEMI; Unfractionated heparin

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTITHROMBIN III; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; STREPTOKINASE; TENECTEPLASE; THROMBIN; THROMBOPLASTIN; TINZAPARIN; TIROFIBAN;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ANTICOAGULATION; AREA UNDER THE CURVE; ARTICLE; BLEEDING; BRAIN HEMORRHAGE; CATHETER THROMBOSIS; CHRONIC KIDNEY DISEASE; CLINICAL TRIAL; CORONARY ARTERY BYPASS GRAFT; COST EFFECTIVENESS ANALYSIS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG COST; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG SAFETY; DRUG STRUCTURE; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HEPARIN INDUCED THROMBOCYTOPENIA; HIGH RISK PATIENT; HUMAN; INCIDENCE; META ANALYSIS; MORTALITY; OBESITY; OSTEOPOROSIS; OUTCOME ASSESSMENT; PARTIAL THROMBOPLASTIN TIME; PATIENT CARE; PATIENT MONITORING; PERCUTANEOUS CORONARY INTERVENTION; PREGNANCY; RISK BENEFIT ANALYSIS; ST SEGMENT ELEVATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

ANGINA, UNSTABLE; ANTICOAGULANTS; CLINICAL TRIALS; ENOXAPARIN; HUMANS; MYOCARDIAL INFARCTION;

EID: 34249336017     PISSN: 14779072     EISSN: 17448344     Source Type: Journal    
DOI: 10.1586/14779072.5.3.387     Document Type: Article

References (55)

1. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin as antithrombin therapy in patients receiving fibrinolysis for ST-elevation myocardial infarction: design and rationale for the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment-Thrombolysis In Myocardial Infarction study 25 (ExTRACT-TIMI 25). Am. Heart J. 149, 217-226 (2005).
2. Budaj A, Breiger D, Steg G et al. Global patterns of use of antithrombic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Syndromes (GRACE). Am. Heart J. 146, 999-1006 (2003).
3. Warkentin TE, Levine MN, Hirsh J et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N. Engl. J. Med. 332(20), 1330-1335 (1995).
4. Rosenberg RD, Bauer KA. The heparin-antithrombin system: a natural anticoagulant mechanism. In: Hemostasis and Thrombosis: Basic Principles and Clinical Practice 3rd Ed. Colman RW, Hirsh J, Marder VJ et al. (Eds.). JB Lippincott, PA, USA, 837-860 (1994).
5. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126, 188S-203S (2004).
6. Bara L, Billaud E, Gramond G et al. Comparative pharmacokinetics of a low molecular weight heparin (PK 10 169) and unfractionated heparin after intravenous and subcutaneous administration. Thromb. Res. 39, 631-636 (1985).
7. Collet JP, Montalescot G, Lison L et al. Percutaneous coronary intervention after subcutaneous enoxaparin pretreatment in patients with unstable angina pectoris. Circulation 103, 658-663 (2001).
8. The Thrombolysis in Myocardial Infarction 11A Trial Investigators. Dose ranging trial of enoxaparin for unstable angina: results of TIMI 11A. J. Am. Coll. Cardiol. 29, 1474-1482 (1997).
9. Rene B, Pascale B, Sylvie R et al. Population pharmacokinetics and pharmacodynamics of enoxaparin in unstable angina non-ST-segment elevation myocardial infarction. Br. J. Clin. Pharmacol. 56, 407-414 (2003).
10. Duplaga BA, Rivers CW, Nutescu E. Dosing and monitoring of low-molecular-weight heparins in special populations. Pharmacotherapy 21, 218-234 (2001).
11. Greaves M. Limitations of the laboratory monitoring of heparin therapy. Scientific and Standardization Committee Communications: on behalf of the Control of Anticoagulation Subcommittee of the Scientific and Standardization Committee of the International Society of Thrombosis and Haemostasis. Thromb. Haemost. 87, 163-164 (2002).
12. The ASSENT-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infraction. Lancet 358, 605-613 (2001).
13. Antman EM, Morrow DA, McCabe CH et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N. Engl. J. Med. 354, 1477-1488(2006).
14. Cadroy Y. Pourrat J, Baladre MF et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb. Res. 63, 385-390 (1991).
15. Nagge J, Crowther M, Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch. Intern. Med. 162, 2605-2609 (2002).
16. Sanderink GJ, Liboux A, Jariwala N et al. The pharmacokinetics and pharmacodynamics of enoxaparin in obese volunteers. Clin. Pharmacol. Ther. 72, 308-318 (2002).
17. Becker RC, Spencer FA, Bruno R et al. Excess body weight does not adversely influence either bioavailability or anticoagulant activity of enoxaparin administered subcutaneously in acute coronary syndromes. Circulation 102(Suppl. 2), 427-428 (2000).
18. Spinler SA, Inverso SM, Cohen M et al. Safety and Efficacy of unfractionated heparin versus enoxaparin in patients who are obese and with severe renal impairment. Analysis from the ESSENCE and TIMI-11B studies. Am. Heart J. 146, 33-41 (2003).
19. Argenti D, Hippensteadt D, Heald D et al. Pharmacokinetics of enoxaparin in patients undergoing percutaneous coronary intervention with and without glycoprotein IIb/IIIa therapy. Am. J. Ther. 10, 241-246 (2003).
20. Michalis LK, Katsouras C, Papamichael N et al. Enoxaparin versus tinzaparin in non-ST-segment elevation acute coronary syndromes: the EVET trial. Am. Heart J. 146(2), 304-310 (2003).
21. The Fifth OASIS Investigators. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N. Engl. J. Med. 354, 1464-1476 (2006).
22. Cohen M, Demers C, Gurfinkel EP et al. Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q Wave Coronary Events Study Group. A comparison of low-molecular weight heparin with unfractionated heparin for unstable coronary artery disease. N. Engl. J. Med. 337, 447 (1997).
23. Antman EM, McCabe CH, Gurfinkel EP et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction: results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 100, 1593-1601(1999).
24. Antman EM, Cohen M, McCabe CH et al. Enoxaparin is superior to unfractionated heparin for preventing clinical events at 1-year follow-up of TIMI 11B and ESSENCE. Eur. Heart J. 23, 308-314 (2002).
25. Blazing MA, de Lemos JA, White HD et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 292, 55 (2004).
26. Ferguson JJ, Califf RM, Antman EM et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 292, 45 (2004).
27. Goodman SG, Fitchett D, Armstrong PW et al. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation 107, 238-244 (2003).
28. Petersen JL, Mahaffey KW, Hasselblad V et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-segment elevation acute coronary syndromes. A systematic overview. JAMA 292, 89-96 (2004).
29. Ross AM, Molhoek P, Lundergan C et al. Randomized comparison of enoxaparin, a low-molecular-weight heparin, with unfractionated heparin adjunctive to recombinant tissue plasminogen activator thrombolysis and aspirin: second trial of Heparin and Aspirin Reperfusion Therapy (HART II). Circulation 104, 648-652 (2001).
30. Simoons M, Krzeminska-Pakula M, Alonso A et al. Improved reperfusion and clinical outcome with enoxaparin as an adjunct to streptokinase thrombolysis in acute myocardial infarction. The AMI-SK study. Eur. Heart J. 23(16), 1282-1290 (2002).
31. Antman EM, Louwerenburg HW, Barrs HF et al. Enoxaparin as adjunctive antithrombin therapy for ST-elevation myocardial infarction: results of the ENTIRE-Thrombolysis in Myocardial Infarction (TIMI) 23 trial. Circulation 105, 1642-1649(2002).
32. Cohen M, Gensini GF, Maritz F et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J. Am. Coll. Cardiol., 42(8), 1348-1356(2003).
33. Baird SH, Menown IB, McBride SJ et al. Randomized comparison of enoxaparin with unfractionated heparin following fibrinolytic therapy for acute myocardial infarction. Eur. Heart J. 23, 627-632 (2002).
34. Wallentin L, Goldstein P, Armstrong PW et al. Efficacy and safety of tenecteplase in combination with the low-molecular-weight-heparin enoxaparin or unfractionated heparin in the prehospital setting: the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 PLUS randomized trial in acute myocardial infarction. Circulation 108(2), 135-142 (2003).
35. Wolinsky FM. Drug-induced metabolic bone disease. Endocrinol. Metab. Clin. North Am. 24(2), 395-420 (1995).
36. Barbour LA, Kick SD, Steiner JF et al. A prospective study of heparin-induced osteoporosis in pregnancy using bone densitometry. Am. J. Obstet. Gynecol. 170(3), 862-869 (1994).
37. Dahlman TC. Osteoporotic fractures and the recurrence of thromboembolism during pregnancy and the puerperium in 184 women undergoing thromboprophylaxis with heparin. Am. J. Obstet. Gynecol. 168(4), 1265-1270 (1993).
38. Monreal M, Lafoz E, Olive A et al. Comparison of subcutaneous unfractionated heparin with a low molecular weight heparin (Fragmin) in patients with venous thromboembolism and contraindications to coumadin. Thromb. Haemost. 71, 7-11 (1994).
39. Pettila V, Leinonen P, Markkola A et al. Post partum bone mineral density in women treated for thromboprophylaxis with unfractionated heparin or LMW heparin. Thromb. Haemost. 87(2), 182-186 (2002).
40. Backos M, Rai R, Thomas E et al. Bone density changes in pregnant women treated with heparin: a prospective, longitudinal study. Hum. Reprod. 14(11), 2876-2880 (1999).
41. Martel N, Lee J, Wells PS. Risk for heparin-induced-thrombocytopenia with unfractionated and low-molecular weight heparin thromboprophylaxis: a meta-analysis. Blood 106(8), 2710-2715 (2005).
42. Prandoni P, Siragusa S, Girolami B. The incidence of heparin-induced-thrombocytopenia in medical patients treated with low-molecular-weight heparin: a prospective cohort study. Blood 106(9), 3049-3054 (2005).
43. Carter CJ, Kelton JG, Hirsch J et al. The relationship between the hemorrhage and antithrombotic properties of low molecular weight heparin in rabbits. Blood 59, 1239-1245 (1982).
44. Young JJ, Kereiakes DJ, Grines CL, for the National Investigators Collaborating on Enoxaparin (NICE) Investigators. Low molecular weight heparin therapy in percutaneous coronary intervention: the NICE 1 and NICE 4 trials. J. Invasive Cardiol. 12(Suppl. E), E14-E18 (2000).
45. Kereiakes DJ, Fry E, Matthai W et al. Combination enoxaparin and abxicimab therapy during percutaneous coronary intervention: "NICE guys finish first". J. Invasive Cardiol. 12(Suppl. A), 1A-5A (2000).
46. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N. Engl. J. Med. 336, 1689-1696 (1997).
47. The EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein IIb/IIIa blockade. Lancet 352, 87-92 (1998).
48. Cohen M, Theroux P, Borzak S et al. Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin: The ACUTE II study. Am. Heart J. 144, 470-477 (2002).
49. Cohen M, Theroux P, Weber S et al. Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int. J. Cardiol. 71, 273-291 (1999).
50. Bhatt DL, Lee BI, Casterella PJ et al. Safety of concomitant therapy with eptifabitide and enoxaparin in patients undergoing percutaneous coronary intervention: results of the Coronary Revascularization Using Integrillin and Single Bolus Enoxaparin Study. J. Am. Coll. Cardiol. 41, 20-25 (2003).
51. Wong GC, Giugliano RP, Antman EM. Use of low-molecular-weight heparins in the management of acute coronary artery syndromes and percutaneous coronary intervention. JAMA 289, 331-342 (2003).
52. Mark DB, Cowper PA, Berkowitz SD et al. Economic assessment of low-molecular-weight heparin (enoxaparin) versus unfractionated heparin in acute coronary syndrome patients. Results from the ESSENCE randomized trial. Circulation 97, 1702-1707 (1998).
53. Detournay B, Huet X, Fagani F et al. Economic evaluation of enoxaparin sodium versus heparin in unstable angina. A French sub-study ofthe ESSENCE trial. Pharmacoeconomics 18, 83-89 (2000).
54. Bosanquet N, Fox KAA. Long-term economic benefits reflect improved clinical outcomes with enoxaparin versus unfractionated heparin in acute coronary syndromes. One-year data. Br. J. Cardiol. 8, 36-37 (2001).
55. Kaul P, Armstrong PW, Cowper PA et al. Economic analysis of the Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT-3) study: costs of reperfusion strategies in acute myocardial infarction. Am. Heart J. 149, 637-644 (2005).